K-Ras
K-Ras (KRAS) is a small GTPase that functions as a molecular switch within the RAS/MAPK signaling network, cycling between inactive GDP-bound and active GTP-bound states to regulate cell proliferation, differentiation, and survival[1][2]. Mechanistically, activated KRAS transduces signals from cell-surface receptors to downstream effectors, including the MAPK/ERK and PI3K/AKT pathways, thereby coordinating cellular growth and stress-response programs[1][3]. Oncogenic mutations impair GTP hydrolysis and maintain persistent KRAS signaling, resulting in sustained activation of proliferative pathways that contribute to tumor initiation, progression, and therapeutic resistance across multiple cancer types, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer[2][3][4]. In disease models, mutant KRAS also reshapes the tumor microenvironment through inflammatory and immune-regulatory signaling, further supporting tumor development and immune evasion[3][2]. Compared with the related RAS isoforms HRAS and NRAS, KRAS is the most frequently altered RAS family member in human cancer and accounts for the majority of oncogenic RAS mutations, highlighting its distinct biological and clinical importance[2][5]. For experimental applications, the development of mutation-selective inhibitors, especially KRAS^G12C^ inhibitors, has established a tractable platform for studying KRAS-dependent signaling and therapeutic resistance mechanisms, although resistance remains a major challenge for long-term clinical efficacy[2][5].
References:
- [1]. K-Ras gene information.
- [2]. Huang L, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. [Content Brief]
- [3]. Uniyal P, et al. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers (Basel). 2025 Feb 25;17(5):785. [Content Brief]
- [4]. Suda K, et al. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010 Mar;29(1):49-60. [Content Brief]
- [5]. Riedl JM, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026 Mar 9;44(3):471-497. [Content Brief]
-
K-Ras Related Products (287)
Related Products (287)
-
BI-1388
0 ImagesCat. No.: HY-115516CAS No.: 1309952-03-1
-
AUBE00
0 ImagesCat. No.: HY-183553CAS No.: 2874214-01-2AUBE00 is an orally active, selective cyclic peptide pan-KRAS inhibitor. AUBE00 selectively binds to the OFF state of KRAS. AUBE00 exhibits anticancer activity against RAS wild-type colorectal cancer. The combination of AUBE00 with Cetuximab (HY-P9905) produces a synergistic antiproliferative effect.
-
KRAS inhibitor-14
0 ImagesCat. No.: HY-146544CAS No.: 2230873-78-4KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC50 of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC50s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers.
-
KRAS G12C inhibitor 16
0 ImagesCat. No.: HY-125874CAS No.: 2349392-79-4KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 39, has an IC50 of 97 nM.
-
KRAS G12V Peptide
0 ImagesCat. No.: HY-P11356CAS No.: 1932689-39-8KRAS G12V Peptide is a polypeptide and epitope derived from KRASG12V. KRAS G12V Peptide forms a stable, high-affinity peptide-HLA class I complex, which is processed and presented by tumor cells and can be recognized by specific TCR. KRAS G12V Peptide is applicable to research related to metastatic lung cancer.
-
KRASG12C IN-12
0 ImagesCat. No.: HY-159163CAS No.: 2093328-45-9KRASG12C IN-12 (compound-1) is a KRASG12C inhibitor. KRASG12C IN-12 (compound-1) can form a ternary complex with intracellular CYPA and the activated KRASG12C mutant.
-
K-Ras-IN-3
0 ImagesCat. No.: HY-159473CAS No.: 3024991-82-7K-Ras-IN-3 (compound 3) is a potent GDP-KRAS G12V inhibitor with an IC50 value of 0.371 nM. K-Ras-IN-3 has the potential for the research of cancer.
-
KRAS G12C-IN-74
0 ImagesCat. No.: HY-181716CAS No.: 3085516-79-3KRAS G12C-IN-74 is an orally active, selective KRASG12C inhibitor with a target IC50 of 43.18 nM. KRAS G12C-IN-74 induces G0/G1 cell cycle arrest and apoptosis in KRASG12C-mutant cancer cells. KRAS G12C-IN-74 is applicable for the research of KRASG12C-mutant pancreatic cancer, colorectal cancer and lung cancer.
-
pan-KRAS-IN-6
0 ImagesCat. No.: HY-162439CAS No.: 3033565-36-2pan-KRAS-IN-6 (compound 12) is a potent pan KRAS inhibitor with IC50 values of 9.79 nM (Kras G12D) and 6.03 nM (Kras G12V).
-
BRSD-212
0 ImagesCat. No.: HY-189619BRSD-212 is an orally active KRAS G12V/G12D inhibitor. BRSD-212 binds the switch-II pocket and inhibits GDP- and GMPPNP-bound mutant KRAS, with IC50 <0.2 nM for both variants. BRSD-212 inhibits ERK phosphorylation in KRAS-mutant tumor cell lines. BRSD-212 induces tumor regression and inhibits tumor growth in xenograft models. BRSD-212 is well tolerated in murine tumor models with no body weight change. BRSD-212 can be used for the research of cancer.
-
Anti-KRAS Antibody
0 ImagesCat. No.: HY-P991743Anti-KRAS Antibody is a human-derived IgG1 kappa monoclonal antibody against KRAS.
-
ZJK-807
0 ImagesCat. No.: HY-178497ZJK-807 is a highly efficient and selective KRASG12D PROTAC degrader (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 promotes KRASG12D ubiquitination and degradation. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer.
-
MS243
0 ImagesCat. No.: HY-181728MS243 is a potent KRASG12D PROTAC degrader with a DC50 of 4.2 nM. MS243 promotes the proximity between KRASG12D and the VHL E3 ubiquitin ligase, drives the ubiquitination and proteasomal degradation of KRASG12D, and inhibits the proliferation of cancer cells harboring KRASG12D. MS243 can be used in the research of KRASG12D-carrying cancers, such as colon cancer and pancreatic cancer.
-
G-quadruplex ligand 4
0 ImagesCat. No.: HY-179480G-quadruplex ligand 4 is a chromenone derivative and is a human telomerase reverse transcriptase (hTERT) G4 ligand. G-quadruplex ligand 4 downregulates hTERT expression and exhibits notable cytotoxicity towards triple-negative breast cancer (TNBC) cell lines. G-quadruplex ligand 4 can cause S/G2 cell cycle arrest and induce apoptosis. G-quadruplex ligand 4 downregulates the expression of hTERT, KRAS, and BCL-2. G-quadruplex ligand 4 can be used for the research of TNBC.
-
pan-KRAS-IN-15
0 ImagesCat. No.: HY-163489CAS No.: 3034052-52-0pan-KRAS-IN-15 (compound 58) is a pan-KRAS inhibitor. pan-KRAS-IN-15 can be used in pancreatic cancer research.
-
L-Azatyrosine
0 ImagesCat. No.: HY-W048303CAS No.: 58525-82-9L-Azatyrosine is an antitumor Antibiotic. L-Azatyrosine is present in Streptomyces chibanensis. L-Azatyrosine inhibits the growth of K-ras-transformed cells without affecting wild-type cells. L-Azatyrosine exhibits anticancer activity against prostate cancer. L-Azatyrosine can be used in studies related to prostate cancer.
-
KRAS-IN-61
0 ImagesCat. No.: HY-187519KRAS-IN-61 is an orally effective pan-KRAS inhibitor that potently inhibits SOS1-mediated KRAS nucleotide exchange (IC50 <10 nM for KRAS G12D/G12V/G12C/WT). KRAS-IN-61 inhibits pERK signaling and cell proliferation in KRAS-mutant tumor cells. KRAS-IN-61 can inhibit tumor growth in vivo. KRAS-IN-61 can be used in studies of KRAS mutation-related cancers, such as colorectal cancer.
-
KRAS G12C degrader-1
0 ImagesCat. No.: HY-153881CAS No.: 2768099-51-8KRAS G12C degrader-1 (compound 283) is a potent KRASG12C chaperone-mediated protein (CHAMP) degrader with DC50 < 100 nM. KRAS G12C degrader-1 binds to KRASG12C and HSP90, inducing ubiquitination and proteasomal degradation of KRASG12C. KRAS G12C degrader-1 can be used for research on KRASG12C-mutant cancers.
-
KRAS inhibitor-13
0 ImagesCat. No.: HY-146543CAS No.: 2230873-96-6KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC50s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers.
